Humana Is Dropping 600,000 Medicare Advantage Members — Florida Has More to Lose Than Any Other State

Humana plans to exit Medicare Advantage plans covering 600,000 members in 2027, focusing on lower profitability plans. Florida, with high MA enrollment, is disproportionately affected. Humana expects to retain 40% of members, leaving 240,000 to find new coverage. Affected members will have a special enrollment period and a Medigap guaranteed issue window. UnitedHealthcare and Elevance Health are also reducing MA memberships, according to Moody's.

Original reporting
Published Aug 27, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 2:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana Is Dropping 600,000 Medicare Advantage Members — Florida Has More to Lose Than Any Other State — source image
Decision brief

The 30-second read

$HUMBearishMed
01

Why it matters

The plan exits could reduce Humana's MA enrollment and revenue, but recapturing members into other offerings may mitigate the impact. Competitors may benefit from displaced members.

02

Market read

The announcement may trigger short‑term weakness in Humana's stock and influence sentiment toward other MA carriers.

03

What to watch

Potential upside from recapturing 40% of members into higher‑margin plans and the broader industry shift toward dual‑eligible and fee‑based business.

Relevance 6/10Novelty 6/10Timing: post‑announcement, impact unfolding through FY2027 enrollment period

Background

Humana is one of the two largest Medicare Advantage carriers in Florida, a state with >60% MA penetration. The company is reshaping its portfolio amid industry‑wide MA declines.

Company-level read

Ticker impact

$HUMBearishMedium confidence
Context

Humana announced it will exit Medicare Advantage plans covering ~600,000 members for 2027, cutting lower‑profitability business.

Expected impact

Downward pressure on HUM stock in the near term as investors price loss of MA revenue.

Evidence & confidence

The exit removes a sizable member base and may signal broader portfolio trimming, affecting earnings outlook.

Market effects

Highlights a trend of MA carriers pruning unprofitable plans, which could pressure other insurers like UnitedHealth (UNH) and Elevance Health (ELV).

Florida's senior market may see increased demand for Medigap and alternative MA products.

Limited to U.S. health‑insurance sector; no direct global impact.

Counterpoint

The exit may improve overall profitability by shedding low‑margin business, potentially supporting the stock if cost savings exceed revenue loss.

Key entities

  • Humana Inc.

    U.S. health insurer exiting ~600,000 Medicare Advantage members.

  • UnitedHealth Group

    Industry peer also expecting MA enrollment decline.

  • Elevance Health

    Industry peer with recent MA membership drop.

Related articles

$UNHHighAI 8/10

Health Insurer Stocks Are Soaring As Companies Get A Handle On Costs

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

$CNCMedAI 8/10

CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Med

Glenmark USA Agrees to USD 15.28 Mn Settlement With Humana Over Generic Drug Antitrust Claims

Glenmark Pharmaceuticals said its U.S. subsidiary, Glenmark USA, agreed to settle with Humana Inc. for $15.28 million, including interest, to resolve antitrust and consumer protection claims over alleged generic drug price-fixing and market allocation. Glenmark USA denies all allegations. The company said the amount is already provided for in its financials and expects no significant financial impact.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.

MedAI 8/10

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

Glenmark Pharmaceuticals Ltd said its US unit, Glenmark Pharmaceuticals Inc., agreed to pay Humana Inc. $15.28 million to settle antitrust litigation over alleged price-fixing and market allocation in generic drugs. Glenmark said it denies all allegations and the settlement is not an admission of liability. The payment is in two installments and already provided for in its financials.